Results 61 to 70 of about 25,089 (208)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations [PDF]

, 2017
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).CYP2C9 is the ...
John Miners, Rettie, Allan E, Douglas Fowler, Fowler, Douglas M, Ann Daly, Daly, Ann K, Allan Rettie, Miners, John Oliver   +7 more
core   +1 more source

Genotype of cytochrome-450 2C9 in patients with tuberculosis [PDF]

Medičnì Perspektivi, 2013
The aim of present work was to investigate CYP2С9 polymorphism in the south of Ukraine in TB-patients and comparing with the same data of control group by the example of Odessa region. Gene CYP2С9 polymorphism was studied with the help of PCR (polymerase
Kresyun V.I., Filyuk V.V., Antonenko P.B., Rogach K.K., Danylenko Yu.M., Mozolevych G.V.   +5 more
doaj  

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

DISTRIBUTION OF POLYMORPHISMS OF GENES OF STATINS METABOLISM AND TRANSPORT IN THE LIVER IN PATIENTS WITH CORONARY ARTERY DISEASE ETHNIC UZBEKS WITH SIMVASTATIN INTOLERANCE

Евразийский Кардиологический Журнал, 2017
Background. It is well-known that in majority of cases treatment with statins can be safe and well tolerated, but in some patients observed statin-induced adverse liver or muscle symptoms - the main reasons for statin discontinuation.
A. B. Shek, R. D. Kurbanov, G. J. Abdullayeva, A. V. Nagai, A. A. Abdullaev, S. S. Ahmedova, S. U. Hoshimov, A. V. Ziyaeva   +7 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage

Терапевтический архив, 2011
Aim. To investigate frequency of carriage of genetic polymorphisms CYP2C9 and VKORC1 in patients with venous thromboembolic complications (VTEC) in Moscow population given warfarin treatment and effects of this carriage on stability of anticoagulation ...
Natal'ya Mikhaylovna Vorob'eva, Elizaveta Pavlovna Panchenko, Anatoliy Borisovich Dobrovol'skiy, Elena Vladimirovna Titaeva, Zukhra Bilyalovna Khasaeva, Nina Valer'evna Konovalova, Anton Yuvenal'evich Postnov, Aleksandr Ivanovich Kirienko, N M Vorobyeva, E P Panchenko, A B Dobrovolsky, E V Titaeva, Z B Khasaeva, N V Konovalova, A Yu Postnov, A I Kirienko   +15 more
doaj  

The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity

Epilepsia Open, EarlyView.
Abstract Epilepsy comprises a highly heterogeneous group of neurological disorders unified by a persistent predisposition to recurrent seizures, yet driven by remarkably diverse genetic, molecular, and network‐level mechanisms. Advances in genomic technologies have revealed that epilepsy arises from a multilayered genetic architecture encompassing rare
Mohammad Reza Seyedtaghia, Jina Babanzadeh, Marcello Scala, Lorenzo Perilli, Pasquale Striano   +4 more
wiley   +1 more source

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations [PDF]

, 2018
\ua9 2018 by the authors. Licensee MDPI, Basel, Switzerland. CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug metabolism. Polymorphisms resulting in decreased enzyme activity
Fowler DM, Miners JO, Daly AK, Rettie AE
core   +4 more sources

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source

CLOPIDOGREL PHARMACOGENETICS

Рациональная фармакотерапия в кардиологии, 2016
Platelets play an important role in the pathogenesis of atherosclerosis. They are involved in atherosclerosis progression and thrombotic complications. That is why antiplatelet therapy is a necessary element of these complications prevention in patients ...
A. N. Meshkov
doaj   +1 more source